Department of Cardiothoracic Surgery, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Guangxi, Nanning, China.
Medicine (Baltimore). 2020 Dec 11;99(50):e21789. doi: 10.1097/MD.0000000000021789.
X inactive specific transcript (XIST) is a novel long noncoding RNA (lncRNA) which has been reported to be frequently upregulated in various human cancer types and to function as an oncogene. It has been reported that the expression of lncRNA XIST was upregulated in non-small cell lung cancer (NSCLC). In the present study, we aimed to investigate the clinical significance and prognostic value of XIST in patients with NSCLC.A total of 156 pairs of NSCLC and corresponding adjacent normal lung tissue samples were obtained from NSCLC patients who had undergone surgery from July 2014 to March 2019. The Student's t test was used in different treated groups for statistical analysis. The association between XIST expression and clinicopathological features of NSCLC patients was evaluated using the chi-squared test. Survival curves were plotted using Kaplan-Meier method and compared by log-rank test.The expression of XIST was significantly higher in NSCLC samples compared to non-cancerous samples (P < .001). Statistically significant correlations were observed between high tissue XIST expression level and lymph node metastasis (P = .036) and high Tumor Node Metastasis (TNM) stage (P = .002). The log-rank test indicated that patients with increased XIST expression experienced poor overall survival (P = .006). Multivariate Cox regression analysis showed that XIST expression level (hazard ratio = 2.645, 95% confidence interval: 1.672-7.393, P = .029) was an independent factors in predicting the overall survival of NSCLC patients.The present study found that XIST expression level was significantly associated with advanced pathological stage and high TNM stage in NSCLC. Furthermore, upregulation of tissue lncRNA XIST predicts poor postoperative survival in patients with NSCLC.
X 失活特异性转录物 (XIST) 是一种新型长非编码 RNA (lncRNA),已报道在多种人类癌症类型中频繁上调,并作为癌基因发挥作用。据报道,lncRNA XIST 的表达在非小细胞肺癌 (NSCLC) 中上调。在本研究中,我们旨在研究 XIST 在 NSCLC 患者中的临床意义和预后价值。
共收集了 156 对 NSCLC 患者手术切除的 NSCLC 组织及其对应的癌旁正常肺组织样本,这些患者均于 2014 年 7 月至 2019 年 3 月接受了手术治疗。采用 Student's t 检验对不同治疗组进行统计学分析。采用卡方检验评估 XIST 表达与 NSCLC 患者临床病理特征的关系。采用 Kaplan-Meier 法绘制生存曲线,并采用对数秩检验进行比较。
XIST 在 NSCLC 组织中的表达明显高于癌旁正常组织(P<0.001)。XIST 组织高表达水平与淋巴结转移(P=0.036)和高肿瘤淋巴结转移(TNM)分期(P=0.002)呈显著相关。对数秩检验表明,XIST 表达增加的患者总生存期较差(P=0.006)。多因素 Cox 回归分析显示,XIST 表达水平(危险比=2.645,95%置信区间:1.672-7.393,P=0.029)是预测 NSCLC 患者总生存期的独立因素。
本研究发现,XIST 表达水平与 NSCLC 的晚期病理分期和高 TNM 分期显著相关。此外,组织 lncRNA XIST 的上调预示着 NSCLC 患者术后生存不良。